161 related articles for article (PubMed ID: 26971879)
1. An Approach to Breast Cancer Immunotherapy: The Apoptotic Activity of Recombinant Anti-Interleukin-6 Monoclonal Antibodies in Intact Tumour Microenvironment of Breast Carcinoma.
Abou-Shousha S; Moaaz M; Sheta M; Motawea MA
Scand J Immunol; 2016 Jun; 83(6):427-37. PubMed ID: 26971879
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic Approach to Breast Cancer: The Anti-Tumor Effect of Anti-IL-6 Monoclonal Antibodies in Malignant Mammary Tumor Implanted-Mice.
Abou-Shousha SA; Abdel-Mawla AAAS; Hassan SM
Egypt J Immunol; 2016 Jan; 23(1):57-66. PubMed ID: 28502153
[TBL] [Abstract][Full Text] [Related]
3. The interplay of interleukin-17A and breast cancer tumor microenvironment as a novel immunotherapeutic approach to increase tumor immunogenicity.
Moaaz M; Lotfy H; Motawea MA; Fadali G
Immunobiology; 2021 Mar; 226(2):152068. PubMed ID: 33556742
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers.
Kendrick JE; Estes JM; Straughn JM; Alvarez RD; Buchsbaum DJ
Gynecol Oncol; 2007 Sep; 106(3):614-21. PubMed ID: 17602728
[TBL] [Abstract][Full Text] [Related]
5. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-8 monoclonal antibodies inhibits the autophagic activity and cancer stem cells maintenance within breast cancer tumor microenvironment.
Abou Shousha S; Osman EM; Baheeg S; Shahine Y
Breast Dis; 2024; 43(1):37-49. PubMed ID: 38552109
[TBL] [Abstract][Full Text] [Related]
7. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
[TBL] [Abstract][Full Text] [Related]
8. Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells.
Younesi V; Nejatollahi F
Int Immunopharmacol; 2014 Dec; 23(2):624-32. PubMed ID: 25466271
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
10. [Combined effect of anti-vascular endothelial growth factor antibody and recombinant human TRAIL on inducing apoptosis of leukemia K562 cells].
Wang AH; Zhong ZM; Zhou XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1163-7. PubMed ID: 21129253
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells.
Miyashita T; Kawakami A; Nakashima T; Yamasaki S; Tamai M; Tanaka F; Kamachi M; Ida H; Migita K; Origuchi T; Nakao K; Eguchi K
Clin Exp Immunol; 2004 Aug; 137(2):430-6. PubMed ID: 15270863
[TBL] [Abstract][Full Text] [Related]
12. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).
Guseva NV; Rokhlin OW; Taghiyev AF; Cohen MB
Breast Cancer Res Treat; 2008 Feb; 107(3):349-57. PubMed ID: 17453339
[TBL] [Abstract][Full Text] [Related]
13. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
14. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
Marini P; Denzinger S; Schiller D; Kauder S; Welz S; Humphreys R; Daniel PT; Jendrossek V; Budach W; Belka C
Oncogene; 2006 Aug; 25(37):5145-54. PubMed ID: 16636678
[TBL] [Abstract][Full Text] [Related]
16. Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells.
Pal S; Shankar BS; Sainis KB
Cytokine; 2013 Oct; 64(1):196-207. PubMed ID: 23972545
[TBL] [Abstract][Full Text] [Related]
17. Chemosensitization of T-47D breast carcinoma cells to TRAIL and Fas receptor-induced killing.
Morgan M; Williams BA; Blay J; Hoskin DW
Anticancer Res; 2002; 22(2A):673-6. PubMed ID: 12014636
[TBL] [Abstract][Full Text] [Related]
18. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
[TBL] [Abstract][Full Text] [Related]
19. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
